Prevalence of In-Stent Restenosis in Patients having Drug Eluting Stents with Lengths Exceeding 40mm: A Single-Center Study

Main Article Content

Muhammad Zubair Khan
Syed Muhammad Nayab Ali
Waqas Ahmad Jan
Amjad Ali Hulio
Noman Ullah Wazir
Deepak Lal


Background: Coronary artery disease (CAD) remains a significant global health challenge, with percutaneous coronary intervention (PCI) being a primary treatment method. The use of long drug-eluting stents (DES) has been linked to varied outcomes, particularly concerning in-stent restenosis (ISR), which may be influenced by factors like stent length and patient comorbidities.

Objective: To assess the prevalence of ISR in patients undergoing PCI with long DES (>40mm), considering patient demographics, comorbidities, and lesion characteristics.

Methods: This cross-sectional study was conducted at Frontier Corps Teaching Hospital (FCTH) and Lady Reading Hospital in Peshawar, Pakistan, involving 102 patients. The study focused on the frequency of ISR post-angioplasty, particularly in relation to comorbid conditions such as diabetes and hypertension. Data collection included demographics, echocardiographic assessments, and detailed angiogram analysis. Statistical analysis was performed using SPSS version 23.0, with a significance threshold set at p<0.05.

Results: The overall prevalence of ISR was found to be 18.63%. Diabetes and hypertension showed a significant association with ISR, with p-values <0.0015. The ISR frequencies for single vessel disease (SVCAD), double vessel disease (DVCAD), and triple vessel disease (TVCAD) were 26.32%, 31.58%, and 42.10%, respectively, with TVCAD showing a statistically significant association (p=0.0185).

Conclusion: The study highlights a significant association between long DES and increased ISR rates, particularly in patients with complex coronary anatomies and multiple comorbidities. Shorter stents are recommended to potentially reduce restenosis and improve outcomes in CAD management.

Article Details

How to Cite
Khan, M. Z., Syed Muhammad Nayab Ali, Waqas Ahmad Jan, Amjad Ali Hulio, Noman Ullah Wazir, & Deepak Lal. (2024). Prevalence of In-Stent Restenosis in Patients having Drug Eluting Stents with Lengths Exceeding 40mm: A Single-Center Study. Journal of Health and Rehabilitation Research, 4(2), 837–841.
Author Biographies

Muhammad Zubair Khan, Frontier Corps Teaching Hospital (FCTH) - Shakas Peshawar - Pakistan.

MBBS, Consultant Cardiologist - Frontier Corps Teaching Hospital (FCTH) - Shakas Peshawar - Pakistan.

Syed Muhammad Nayab Ali, Lady Reading Hospital - Peshawar - Pakistan.

MBBS, PGR Cardiology - Lady Reading Hospital - Peshawar - Pakistan.

Waqas Ahmad Jan, Mardan Medical Complex - Mardan - Pakistan.

MBBS, Trainee Medical Officer of Cardiology - Mardan Medical Complex - Mardan - Pakistan.

Amjad Ali Hulio, National Institute of Cardiovascular Diseases (NICVD) Larkana Centre - Pakistan.

MBBS, Assistant Professor - National Institute of Cardiovascular Diseases (NICVD) Larkana Centre - Pakistan.

Noman Ullah Wazir, Peshawar Medical College - Peshawar - Pakistan.

MBBS, MPhil, PhD, Associate Professor of Anatomy - Peshawar Medical College - Peshawar - Pakistan.

Deepak Lal, Pakistan and Zayed Military Hospital - Abu Dhabi - UAE.

MBBS, FCPS, Adult Cardiology - NICVD Karachi - Pakistan and Zayed Military Hospital - Abu Dhabi - UAE.


Bansal, A., & Hiwale, K. (2023). Updates in the Management of Coronary Artery Disease: A Review Article. Cureus, 15(12), e50644.

GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1736-1788.

Omeh DJ, Shlofmitz E. Restenosis of Stented Coronary Arteries. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from:

Borhani, S., Hassanajili, S., Ahmadi Tafti, S. H., & Rabbani, S. (2018). Cardiovascular stents: overview, evolution, and next generation. Progress in biomaterials, 7(3), 175–205.

Her, A. Y., & Shin, E. S. (2018). Current Management of In-Stent Restenosis. Korean circulation journal, 48(5), 337–349.

Ananthakrishna, R., Loh, J. P., Shen, L., Low, A. F., Lee, C. H., & Tan, H. C. (2018). Selective use of drug-eluting stents in high-risk versus bare metal stents in low-risk patients according to predefined criteria confers similar four-year long-term clinical outcomes. AsiaIntervention, 4(2), 87–91.

Pal, N., Din, J., & O'Kane, P. (2019). Contemporary Management of Stent Failure: Part One. Interventional cardiology (London, England), 14(1), 10–16.

Scarsini, R., Fezzi, S., Leone, A. M., De Maria, G. L., Pighi, M., Marcoli, M., Tavella, D., Pesarini, G., Banning, A. P., Barbato, E., Wijns, W., & Ribichini, F. L. (2022). Functional Patterns of Coronary Disease: Diffuse, Focal, and Serial Lesions. JACC. Cardiovascular interventions, 15(21), 2174–2191.

Sinha, S. K., Aggarwal, P., Pandey, U., Razi, M., Kumar, A., & Krishna, V. (2021). Ultrathin (60 μm), ultralong (≥40 mm) sirolimus-eluting stent: study of clinical and safety profiles among real-world patients. Anatolian journal of cardiology, 25(2), 111–119.

Gherasie, F. A., Valentin, C., & Busnatu, S. S. (2023). Is There an Advantage of Ultrathin-Strut Drug-Eluting Stents over Second- and Third-Generation Drug-Eluting Stents?. Journal of personalized medicine, 13(5), 753.

Rajesh, G. N., Sulaiman, S., Vellani, H., & Sajeev, C. G. (2018). One-year clinical outcome of percutaneous coronary intervention with very long (≥ 40mm) drug-eluting stent. Indian heart journal, 70 Suppl 3(Suppl 3), S285–S289.

Angsubhakorn, N., Kang, N., Fearon, C., Techorueangwiwat, C., Swamy, P., Brilakis, E. S., & Bharadwaj, A. S. (2022). Contemporary Management of Severely Calcified Coronary Lesions. Journal of personalized medicine, 12(10), 1638.

Wang, P., Qiao, H., Wang, R. et al. The characteristics and risk factors of in-stent restenosis in patients with percutaneous coronary intervention: what can we do. BMC Cardiovasc Disord 20, 510 (2020).

Qin SY, Zhou Y, Jiang HX, et al. The association of diabetes mellitus with clinical outcomes after coronary stenting: a meta-analysis. PLoS One. 2013;8:e72710.

Wihanda D, Alwi I, Yamin M, et al. Factors associated with in-stent restenosis in patients following percutaneous coronary intervention. Acta Med Indones. 2015;47:209–215

Li M, Hou J, Gu X, Weng R, Zhong Z, Liu S. Incidence and risk factors of in-stent restenosis after percutaneous coronary intervention in patients from southern China. European Journal of Medical Research. 2022 Jan 22;27(1):12.

Shimono H, Kajiya T, Takaoka J, Miyamura A, Inoue T, Kitazono K, Ninomiya T, Atsuchi Y, Atsuchi N, Ohishi M. Characteristics of recurrent in-stent restenosis after second-and third-generation drug-eluting stent implantation. Coronary Artery Disease. 2021 Jan 1;32(1):36-41.

Bhatia K, Akhtar IN, Akinci Y, Liaqat J, Siddiq F, Gomez CR, Qureshi AI. Drug‐Eluting Balloon Angioplasty for in‐Stent Restenosis Following Carotid Artery Stent Placement. Journal of Neuroimaging. 2020 May;30(3):267-75.

Condello F, Spaccarotella C, Sorrentino S, Indolfi C, Stefanini GG, Polimeni A. Stent thrombosis and restenosis with contemporary drug-eluting stents: predictors and current evidence. Journal of Clinical Medicine. 2023 Feb 3;12(3):1238.

Kurata N, Iida O, Asai M, Masuda M, Okamoto S, Ishihara T, Nanto K, Mano T. Factors influencing in-stent occlusion after femoropopliteal artery stent placement with intravascular ultrasound evaluation. Journal of Vascular and Interventional Radiology. 2020 Feb 1;31(2):213-20.